TY - JOUR
T1 - Adalimumab for Ocular Inflammation
AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group
AU - Durrani, Khayyam
AU - Kempen, John H.
AU - Ying, Gui shuang
AU - Kacmaz, R. Oktay
AU - Artornsombudh, Pichaporn
AU - Rosenbaum, James T.
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Jabs, Douglas A.
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Foster, C. Stephen
N1 - Funding Information:
This study was supported primarily by National Eye Institute Grant EY014943 (JHK), and the Ocular Immunology and Uveitis Foundation (Cambridge, MA). Additional support was provided by National Eye Institute Grant P30 EY001583, Research to Prevent Blindness (RPB, New York, NY), and the Paul and Evanina Mackall Foundation (New York, NY) provided additional support. JHK was an RPB James S. Adams Special Scholar Award recipient. JTR and DAJ were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. EBS receives support from the Department of Veterans’ Affairs. JET was an RPB Harrington Special Scholar Award recipient. GAL-C was previously supported by, and RBN continues to be supported by, intramural funds of the National Eye Institute. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript.
Publisher Copyright:
© Taylor & Francis Group, LLC.
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.
AB - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.
KW - Adalimumab
KW - Humira
KW - TNF-α antibody
KW - ocular inflammatory disease
KW - scleritis
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=84961390336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961390336&partnerID=8YFLogxK
U2 - 10.3109/09273948.2015.1134581
DO - 10.3109/09273948.2015.1134581
M3 - Article
C2 - 27003323
AN - SCOPUS:84961390336
SN - 0927-3948
VL - 25
SP - 405
EP - 412
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 3
ER -